To investigate the von Willebrand factor to ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma (HCC) in cirrhosis. Serum levels of alpha-fetoprotein, des-γ-carboxy prothrombin, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (alpha-fetoprotein-L3%), vascular endothelial growth factor, and vascular endothelial growth factor receptor-2, as well as the plasma levels of von Willebrand factor antigen (von Willebrand factor: Ag) and ADAMTS13 activity (ADAMTS13:AC), were evaluated in 41 cirrhotic patients with HCC undergoing radiofrequency ablation and in 20 cirrhotic patients without HCC. The diagnostic accuracy of each biomarker was evaluated using the receiver operating characteristic curve analysis. The von Willebrand factor: Ag and von Willebrand factor: Ag/ADAMTS13:AC ratios were significantly higher in cirrhotic patients with HCC than in those without HCC (p < 0.05 and p < 0.01, respectively), whereas ADAMTS13:AC was significantly lower in those with HCC than those without HCC (p < 0.05). However, no relationship was observed between the von Willebrand factor: Ag/ADAMTS13:AC ratio and serum tumor markers such as alpha-fetoprotein, des-γ-carboxy prothrombin, and alpha-fetoprotein-L3%. Multivariate regression analysis identified von Willebrand factor: Ag/ADAMTS13:AC ratio and alpha-fetoprotein-L3% as significant factors of HCC development. Receiver operating characteristic analysis showed that the von Willebrand factor: Ag/ADAMTS13:AC ratio and alpha-fetoprotein-L3% had a better performance than alpha-fetoprotein, des-γ-carboxy prothrombin, alpha-fetoprotein-L3%, vascular endothelial growth factor, and vascular endothelial growth factor receptor-2, von Willebrand factor: Ag, and ADAMTS13:AC. The von Willebrand factor: Ag/ADAMTS13:AC ratio was exclusively correlated with tumor volume and stage as well as serum vascular endothelial growth factor levels. The von Willebrand factor: Ag/ADAMTS13:AC ratio can potentially serve as a novel biomarker for early diagnosis of HCC in cirrhotic patients.

中文翻译：

---

VWF / ADAMTS13比值可作为早期检测肝细胞癌的潜在生物标志物

为了研究von Willebrand因子与ADAMTS13的比率，作为早期检测肝硬化中肝细胞癌（HCC）的潜在生物标志物。血清甲胎蛋白，去γ-羧基凝血酶原，扁豆凝集素反应性甲胎蛋白的含量（甲胎蛋白-L3％），血管内皮生长因子和血管内皮生长因子受体2，以及在41例接受射频消融的肝癌肝硬化患者和20例无HCC肝硬化患者中，评估了其血浆von Willebrand因子抗原（von Willebrand factor：Ag）和ADAMTS13活性（ADAMTS13：AC）的水平。使用接收器工作特征曲线分析评估每种生物标记物的诊断准确性。von Willebrand因子：Ag和von Willebrand因子：Ag / ADAMTS13：肝硬化肝癌患者的AC比率显着高于无肝癌的患者（分别为p <0.05和p <0.01），而肝癌的ADAMTS13：AC显着低于无肝癌的患者（p <0.05）。然而，在von Willebrand因子：Ag / ADAMTS13：AC比例与血清肿瘤标志物（如甲胎蛋白，脱γ-羧基凝血酶原和甲胎蛋白-L3％）之间未发现相关性。多元回归分析确定von Willebrand因子：Ag / ADAMTS13：AC比和α-甲胎蛋白-L3％是肝癌发生的重要因素。受体工作特性分析表明，von Willebrand因子：Ag / ADAMTS13：AC比和α-甲胎蛋白-L3％的性能优于α-甲胎蛋白，des-γ-羧基凝血酶原，α-甲胎蛋白-L3％，血管内皮生长因素，血管内皮生长因子受体2，von Willebrand因子：Ag和ADAMTS13：AC。von Willebrand因子：Ag / ADAMTS13：AC比率与肿瘤的大小和分期以及血清血管内皮生长因子水平密切相关。von Willebrand因子：Ag / ADAMTS13：AC比率可作为肝硬化患者早期诊断HCC的新型生物标志物。